Autologous Transplantation Is the Strongest Prognostic Factor for Overall Survival in Multiple Myeloma Patients With Deletion 17p: 20-Year Real-World Experience of the Greek Myeloma Study Group

被引：0

作者：

Katodritou, Eirini ^{[1
]}

Kastritis, Efstathios ^{[2
]}

Dalampira, Dimitra ^{[1
]}

Spanoudakis, Emmanouil ^{[3
]}

Pouli, Anastasia ^{[4
]}

Delimpasi, Sosana ^{[5
]}

Sevastoudi, Aggeliki ^{[1
]}

Ntanasis-Stathopoulos, Ioannis ^{[2
]}

Theodorakakou, Foteini ^{[2
]}

Triantafyllou, Theodora ^{[1
]}

Fotiou, Despina ^{[2
]}

Daiou, Aikaterini ^{[1
]}

Koutoukoglou, Prodromos ^{[1
]}

Tsirou, Kyriaki ^{[1
]}

Kyriakidis, Gerasimos ^{[4
]}

Migkou, Magdalini ^{[2
]}

Kyrtsonis, Marie-Christine ^{[6
,7
]}

Kotsopoulou, Maria

Kostopoulos, Ioannis ^{[8
]}

Gavriatopoulou, Maria ^{[2
]}

Verrou, Evgenia ^{[1
]}

Dimopoulos, Meletios ^{[2
]}

Terpos, Evangelos ^{[2
]}

机构：

[1] Theagenio Canc Hosp, Dept Hematol, Thessaloniki, Greece

[2] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

[3] Univ Hosp Alexandroupolis, Dept Hematol, Alexandroupolis, Greece

[4] Agios Savvas Canc Hosp, Dept Hematol, Athens, Greece

[5] Gen Hosp Evangelismos, Athens, Greece

[6] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Dept Propaedeut Internal Med 1, Athens, Greece

[7] Metaxa Canc Hosp, Dept Haematol, Piraeus, Greece

[8] Natl & Kapodistrian Univ Athens, Sch Sci, Dept Biol, Flow Cytometry Unit, Athens, Greece

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-224

引用

页码：S166 / S167

页数：2

共 38 条

[31] SERUM ANGIOPOIETIN-1 TO ANGIOPOIETIN-2 RATIO IS AN INDEPENDENT PROGNOSTIC FACTOR FOR SURVIVAL IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA: RESULTS FROM THE GREEK MYELOMA STUDY GROUP ON 174 PATIENTS
Terpos, E.
Anargyrou, K.
Katodritou, E.
Kastritis, E.
Pouli, A.
Michali, E.
Delimpasi, S.
Verrou, E.
Margaritis, D.
Tsionos, K.
Stefanoudaki, K.
Zervas, K.
Dimopoulos, M. A.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 77 - 78
[32] EVALUATION OF OVERALL SURVIVAL ASSOCIATED WITH CHANGE IN DOSING OF BORTEZOMIB, MELPHALAN, AND PREDNISONE REGIMEN IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A REAL-WORLD STUDY
Mehra, M.
Potluri, R.
Lam, A.
Slavcev, M.
VALUE IN HEALTH, 2019, 22 : S113 - S113
[33] Real-world outcomes of triple-class exposed multiple myeloma patients by treatment experience: the assocaition of prior lines and penta-refractoriness with progression-free and overall survival
Meche, Aster
Rondeau, Felix
Faucher, Ariane
Ren, Jinma
Schepart, Alexander
Hlavacek, Patrick
Farrell, James
Aydin, Didem
Nador, Guido
DiBonaventura, Marco
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S172 - S173
[34] Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study
Cowan, Andrew J.
Gras, Luuk
Takamatsu, Hiroyuki
Koster, Linda
Baaij III, Laurien
Hamad, Nada
D'Souza, Anita
Estrada-Merly, Noel
Hari, Parameswaran N.
Saber, Wael
Iida, Minako
Okamoto, Shinichiro
Mizuno, Shohei
Kawamura, Koji
Kodera, Yoshihisa
Ko, Bor-Sheng
Liam, Christopher
Wah, Kim
Goh, A. Sim
Tan, S. Keat
Elhaddad, Alaa M.
Bazarbachi, Ali
Chaudhry, Brig Qamar Un N.
Alfar, Rozan
Bekadja, Mohamed Amine
Benakli, Malek
Ortiz, Cristobal Augusto Frutos
Riva, Eloisa
Galeano, Sebastian
Bass, Francisca
Mian, Hira
Mccurdy, Arleigh
Wang, Feng-Rong
Lv, Meng
Neumann, Daniel
Koh, Mickey Boon Chai
Snowden, John
Schonland, Stefan
Mclornan, Donal P.
Hayden, Patrick John
de la Camara, Rafael
Greco, Raffaella
Ciceri, Fabio
Hazenberg, Mette D.
Balari, Anna Sureda
Rondelli, Damiano
Greinix, Hildegard T.
Aljurf, Mahmoud
Atsuta, Yoshiko
Niederwieser, Dietger W.
BLOOD, 2024, 144 : 2379 - 2381
[35] Improved Survival for Multiple Myeloma in Denmark Based on Autologous Stem Cell Transplantation and Novel Drug Therapy in Collaborative Trials: Analysis of Accrual, Prognostic Variables, Selection Bias, and Clinical Behavior on Survival in More Than 1200 Patients in Trials of the Nordic Myeloma Study Group
Johnsen, Hans E.
Klausen, Tobias W.
Boegsted, Martin
Lenhoff, Stig
Gimsing, Peter
Christiansen, Ilse
Gedde-Dahl, Tobias
Lindas, Roald
Mellqvist, Ulf-Henrik
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (04): : 290 - 296
[36] Impact of Cytogenetic Abnormalities, Induction and Maintenance Regimens on Outcomes After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma: A Decade-Long Real-World Experience
Thurlapati, Aswani
Wesson, William
Davis, James A.
Gaffney, Kelly J.
Weeda, Erin
Velayati, Arash
Bakos, Jonathan K.
Granger, Katelynn
Smith, Deidra
Maldonado, Andy P.
Herrington, Taylor
Potts, Julia
Hashmi, Hamza
JOURNAL OF HEMATOLOGY, 2023, 12 (06) : 243 - 254
[37] Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group
Grzasko, Norbert
Hajek, Roman
Hus, Marek
Chocholska, Sylwia
Morawska, Marta
Giannopoulos, Krzysztof
Czarnocki, Krzysztof
Druzd-Sitek, Agnieszka
Pienkowska-Grela, Barbara
Rygier, Jolanta
Usnarska-Zubkiewicz, Lidia
Dytfeld, Dominik
Kubicki, Tadeusz
Jurczyszyn, Artur
Korpysz, Maciej
Dmoszynska, Anna
LEUKEMIA & LYMPHOMA, 2017, 58 (09) : 2089 - 2100
[38] Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group (vol 58, pg 1, 2017)
Grzasko, R.
Hajek, R.
Hus, M.
LEUKEMIA & LYMPHOMA, 2017, 58 (10) : 2518 - 2518

← 1 2 3 4 →